Sanmenxia Central Hospital Report issue

Academic/Hospital Phase 3
Founded: Henan China

Organization Overview

First Clinical Trial
2014
NCT02025036
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Sanmenxia Central Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Cholangiocarcinoma (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5